1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > EpiCast Report: Chronic Hepatitis B - Epidemiology Forecast to 2024

EpiCast Report: Chronic Hepatitis B - Epidemiology Forecast to 2024

Summary

The Hepatitis B Virus (HBV) can cause both acute and chronic liver disease. HBV is typically transmitted through contact with infectious blood or bodily fluid, including vertical transmission from mother to child at birth and transmission via sexual intercourse. Risk factors of chronic hepatitis B (CHB) include unprotected sex with an infected partner, men who have sex with men (MSM), intravenous drug injection (IDU), and a previous history of a sexually transmitted disease (STD). CHB has a well-established comorbidity association with hepatitis C virus (HCV) infection, hepatitis D virus (HDV) infection, human immunodeficiency virus (HIV) infection, and alcohol abuse. The disease often starts as asymptomatic in the acute infection phase, with symptoms beginning to present 30 to 180 days from infection. When symptoms develop, they present as nausea, vomiting, loss of appetite, flu-like symptoms, and jaundice. Severe cases of HBV infection increase the risk of developing liver cancer and cirrhosis.

GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of chronic hepatitis B (CHB) in the 8MM, from 10,557,407 cases in 2014 to 10,861,653 cases in 2024, at an Annual Growth Rate (AGR) of 0.29% in the forecast period. The distribution of diagnosed prevalent chronic hepatitis B cases in the 8MM was greater in men (7,379,948 cases, 69.90% in 2014) than in women (3,177,459 cases, 30.10% in 2014). This skew towards men was found to be consistent across all markets.

GlobalData’s epidemiological forecast for the diagnosed prevalent cases of CHB are supported by age- and sex-specific data obtained from country-specific studies published in peer-reviewed journals, in which the study populations are representative of the general population in the respective markets. The diagnosed prevalent cases are further segmented into ALT level, HBV DNA level, HBeAg status, cirrhosis status, and co-infection with hepatitis C and HIV, thus providing a comprehensive view of the characteristics of CHB patients in the 8MM. Additionally, GlobalData epidemiologists used the same methodology across the 8MM, which allows for a meaningful comparison of the forecast diagnosed incident cases and diagnosed prevalent cases of CHB in these markets.

Scope

- The Chronic Hepatitis B (CHB) EpiCast Report provides an overview of the risk factors and global trends of CHB in the 8MM (US, France, Germany, Italy, Spain, UK, Japan, and China). It includes a 10-year epidemiological forecast for total and diagnosed prevalent cases of CHB segmented by sex and in these markets. The diagnosed prevalent cases of CHB are further segmented by hepatitis B virus (HBV) DNA level (<2000IU/mL, 2,000-20,000IU/mL, and >20,000IU/mL in the US and the 5EU, and <1000IU/mL, 1,000-10,000IU/mL, and >10,000IU/mL in Japan and China), alanine aminotransferase (ALT) level (=2 upper limit of normal [ULN] 2-5ULN and >5ULN), hepatitis e surface antigen (HBeAg) status, and the liver cirrhosis status.
- The CHB epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy

The CHB EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global CHB market.
- Quantify patient populations in the global CHB market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for CHB therapeutics in each of the markets covered.
- Identify the percentage of CHB diagnosed prevalent cases by various clinical segmentations.

Table Of Contents

EpiCast Report: Chronic Hepatitis B - Epidemiology Forecast to 2024
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 8
2.3 Upcoming Related Reports 9
3 Epidemiology 10
3.1 Disease Background 10
3.2 Risk Factors and Comorbidities 11
3.3 Global Trends 12
3.4 Forecast Methodology 14
3.4.1 Sources Used 15
3.4.2 Sources Not Used 24
3.4.3 Forecast Assumptions and Methods 25
3.5 Epidemiological Forecast of Chronic Hepatitis B (2014-2024) 31
3.5.1 Diagnosed Prevalent Cases of Chronic Hepatitis B 31
3.5.2 Age-Specific Diagnosed Prevalent Cases of Chronic Hepatitis B 33
3.5.3 Sex-Specific Diagnosed Prevalent Cases of Chronic Hepatitis B 36
3.5.4 Age-Standardized Diagnosed Prevalence of Chronic Hepatitis B 38
3.5.5 Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented by HBV DNA Level 39
3.5.6 Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented by ALT Level 41
3.5.7 Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented by HBeAg Status 42
3.5.8 Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented by Cirrhosis Status 43
3.5.9 Diagnosed Prevalent Cases of Chronic Hepatitis B with Co-infection of HIV and Hepatitis C 45
3.6 Discussion 46
3.6.1 Epidemiological Forecast Insight 46
3.6.2 Limitations of the Analysis 46
3.6.3 Strengths of the Analysis 47
4 Appendix 48
4.1 Bibliography 48
4.2 About the Authors 51
4.2.1 Epidemiologists 51
4.2.2 Reviewers 51
4.2.3 Global Director of Therapy Analysis and Epidemiology 52
4.2.4 Global Head of Healthcare 52
4.3 About GlobalData 53
4.4 About EpiCast 53
4.5 Disclaimer 54

1.1 List of Tables
Table 1: Risk Factors and Comorbidities for Chronic Hepatitis B 12
Table 2: 8MM, Sources Used for the Diagnosed Prevalent Cases Forecast of Chronic Hepatitis B in the 8MM 15
Table 3: 8MM, Sources Used for HBV DNA Level 16
Table 4: 8MM, Sources Used for Chronic Hepatitis B by ALT Level 16
Table 5: 8MM, Sources Used for Chronic Hepatitis B HBeAg Status 17
Table 6: 8MM, Sources Used for Cirrhosis Status 18
Table 7: 8MM, Sources Used for HIV Co-infection 19
Table 8: 8MM, Sources Used for Hepatitis C Co-infection 20
Table 9: 8MM, Diagnosed Prevalent Cases of Chronic Hepatitis B, Both Sexes, All Ages, Select Years, 2014-2024 32
Table 10: 8MM, Age-Specific Diagnosed Prevalent Cases of Chronic Hepatitis B, Ages ?18 Years, N (Row %), 2014 34
Table 11: 8MM, Sex-Specific Diagnosed Prevalent Cases of Chronic Hepatitis B, Ages ?18 Years, N, 2014 37
Table 12: US and 5EU, Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented by HBV DNA, Ages ?18 Years, N, Both Sexes, 2014 40
Table 13: Japan and China, Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented by HBV DNA, Ages ?18 Years, N, Both Sexes, 2014 40
Table 14: 8MM, Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented by ALT Level, Ages ?18 Years, N, Both Sexes, 2014 42
Table 15: 8MM, Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented by HBeAg Status, Ages ?18 Years, N, Both Sexes, 2014 43
Table 16: 8MM, Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented Cirrhosis Status, Ages ?18 Years, N, Both Sexes, 2014 44
Table 17: 8MM, Diagnosed Prevalent Chronic Hepatitis B Cases Segmented by Co-infection with HIV and Hepatitis C, Both Sexes, Ages ?18 Years, N (% of Diagnosed Chronic Hepatitis B Cases), 2014 45

1.2 List of Figures
Figure 1: 8MM, Diagnosed Prevalent Cases of Chronic Hepatitis B, Both Sexes, Ages ?18 Years, Select Years, 2014-2024 33
Figure 2: 8MM, Age-Specific Diagnosed Prevalent Cases of Chronic Hepatitis B, Ages ?18 Years, Both Sexes, N, 2014 35
Figure 3: 8MM, Sex-Specific Diagnosed Prevalent Cases of Chronic Hepatitis B, Ages ?18 Years, N, 2014 38
Figure 4: 8MM, Age-Standardised Diagnosed Prevalence of Chronic Hepatitis B, Ages ?18 Years, 2014 39

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Liver Cirrhosis- Market Insights, Epidemiology and Market Forecast-2023

Liver Cirrhosis- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Liver Cirrhosis - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global ...

Peptic Ulcer  - Market Insights, Epidemiology and Market Forecast-2023

Peptic Ulcer  - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Peptic Ulcer - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global ...

Crohn’s disease (CD)- Market Insights, Epidemiology and Market Forecast-2023

Crohn’s disease (CD)- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Crohn’s disease (CD) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.